Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published online July 22 in Pediatrics.

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.